The Company
Atlas Antibodies was founded in 2006 by researchers at the Royal Institute of Technology (KTH) in Stockholm and the Rudbeck Laboratory, Uppsala University in Uppsala, Sweden. Atlas Antibodies handles the production, marketing and sales of the antibody products developed and validated in the Human Protein Atlas (HPA) project.
The Human Protein Atlas (HPA) project is performing a systematic exploration of the human proteome with Affinity (Antibody) based Proteomics, combining high-throughput generation of affinity-purified polyclonal antibodies with protein profiling using tissue microarrays. The HPA project is located in Stockholm and Uppsala, Sweden and is funded by the Knut and Alice Wallenberg Foundation. The HPA project generates expression and localization patterns of proteins in a large portion of both normal and cancer human tissues and organs resulting in the antibody-based profiling presented in the publicly available Human Protein Atlas (HPA) portal (www.proteinatlas.org). The HPA vision is to enable the systematic generation of quality assured antibodies to all non-redundant human proteins and to use these reagents to functionally explore human proteins, protein variants and protein interactions.
The Human Protein Atlas (HPA) project is performing a systematic exploration of the human proteome with Affinity (Antibody) based Proteomics, combining high-throughput generation of affinity-purified polyclonal antibodies with protein profiling using tissue microarrays. The HPA project is located in Stockholm and Uppsala, Sweden and is funded by the Knut and Alice Wallenberg Foundation. The HPA project generates expression and localization patterns of proteins in a large portion of both normal and cancer human tissues and organs resulting in the antibody-based profiling presented in the publicly available Human Protein Atlas (HPA) portal (www.proteinatlas.org). The HPA vision is to enable the systematic generation of quality assured antibodies to all non-redundant human proteins and to use these reagents to functionally explore human proteins, protein variants and protein interactions.
Business Areas
Research Reagents
Atlas Antibodies' research reagents catalogue currently consists of 12.300 primary antibodie. The Atlas Antibodies are polyclonal antibodies developed for research use.
The Atlas Antibodies product line is expected to increase with approximately 2,500 new products every year for the next four years in an effort to cover all human proteins by 2015.
Biomarker Discovery
Atlas Antibodies has access to a unique platform for biomarker discovery, including screening of 3,000 human proteins annually, validation of potential cancer markers in large cohorts of cancer specific patient samples, development of target specific monoclonal antibodies and epitope mapping of defined binding sites for the antibodies.
The screening and validation phases are performed in collaboration with the HPA project, set up to perform systematic protein expression profiling of human tissue and cell samples, including normal and cancer samples, in a high throughput manner. In this process, proteins with differential expression patterns in normal and/or cancer samples are discovered. Such proteins are further studied in larger patient cohorts to validate a specific protein's potential as a cancer marker for diagnostic, prognostic and/or treatment predictive use. Monoclonal antibodies are developed against validated biomarkers and the target-binding site for the antibodies is defined by epitope mapping.
Through this unique discovery platform novel cancer markers, such as RBM3, have been identified. The RBM3 biomarker, and other biomarkers are available for licensing and Atlas Antibodies is seeking a strategic partner for development of novel cancer diagnostic and prognostic products.
Atlas Antibodies' research reagents catalogue currently consists of 12.300 primary antibodie. The Atlas Antibodies are polyclonal antibodies developed for research use.
The Atlas Antibodies product line is expected to increase with approximately 2,500 new products every year for the next four years in an effort to cover all human proteins by 2015.
Biomarker Discovery
Atlas Antibodies has access to a unique platform for biomarker discovery, including screening of 3,000 human proteins annually, validation of potential cancer markers in large cohorts of cancer specific patient samples, development of target specific monoclonal antibodies and epitope mapping of defined binding sites for the antibodies.
The screening and validation phases are performed in collaboration with the HPA project, set up to perform systematic protein expression profiling of human tissue and cell samples, including normal and cancer samples, in a high throughput manner. In this process, proteins with differential expression patterns in normal and/or cancer samples are discovered. Such proteins are further studied in larger patient cohorts to validate a specific protein's potential as a cancer marker for diagnostic, prognostic and/or treatment predictive use. Monoclonal antibodies are developed against validated biomarkers and the target-binding site for the antibodies is defined by epitope mapping.
Through this unique discovery platform novel cancer markers, such as RBM3, have been identified. The RBM3 biomarker, and other biomarkers are available for licensing and Atlas Antibodies is seeking a strategic partner for development of novel cancer diagnostic and prognostic products.